NVO vs XERS
NVO: A leading global healthcare company with a heritage in diabetes, pioneering scientific breakthroughs to defeat serious chronic diseases through innovative medicines and expanded access. XERS: A commercial-stage biopharma company with three FDA-approved therapies for rare endocrine and neurological diseases and a proprietary injectable drug formulation platform for rare diseases.
Side-by-side fundamentals
| Metric | NVO | XERS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $48.19 | $8.38 | |
| Market cap as of 2026-07-23 | $219.8B | $1.5B | |
| P/E as of 2026-07-23 | 11.78 | 123.28 | NVO lower |
| PEG as of 2026-07-23 | 16.16 | 2.29 | XERS lower |
| Net margin as of 2026-07-23 | +37.2% | +3.8% | NVO higher |
| Gross margin as of 2026-07-23 | +81.8% | +85.9% | XERS higher |
| Operating margin as of 2026-07-23 | +45.3% | +11.4% | NVO higher |
| ROE as of 2026-07-23 | +66.4% | +99.7% | XERS higher |
| ROA as of 2026-07-23 | +23.3% | +3.2% | NVO higher |
| Debt / equity as of 2026-07-23 | 0.72 | 17.00 | NVO lower |
| Revenue growth (YoY) as of 2026-07-23 | +8.1% | +41.5% | XERS higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +38.3% | |
| Dividend yield as of 2026-07-23 | +3.7% | n/a | |
| Beta as of 2026-07-23 | 1.85 | 0.75 | |
| 1-year return as of 2026-07-22 close | -23.8% | +63.7% | XERS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.